Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors

Noe, Olivia; Ngo, Nealie Tan; Lin, Leslie; Stanbery, Laura; Creeden, Justin; Hamouda, Danae; Nemunaitis, John

doi:10.1016/j.currproblcancer.2022.100917

Cited by 27 publications

(14 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Folate receptor a (FRa) and FRb are membrane-bound proteins anchored to the extracellular surface using glycosylphosphatidylinositol and are capable of transporting folate across membranes via endocytosis (51). FRa is mainly expressed at low levels in epithelial tissues, whereas FRb is found in placental and hematopoietic tissues (51). FRa is highly expressed in osteosarcoma, and FRb+ tumor-associated macrophages have been detected in metastatic osteosarcoma (52,53).…”

Section: Folate Receptor and Ec17mentioning

confidence: 99%

Current status and future challenges of CAR-T cell therapy for osteosarcoma

Li,

Zhang,

Shang

2023

Front. Immunol.

View full text Add to dashboard Cite

Osteosarcoma, the most common bone malignancy in children and adolescents, poses considerable challenges in terms of prognosis, especially for patients with metastatic or recurrent disease. While surgical intervention and adjuvant chemotherapy have improved survival rates, limitations such as impractical tumor removal or chemotherapy resistance hinder the treatment outcomes. Chimeric antigen receptor (CAR)-T cell therapy, an innovative immunotherapy approach that involves targeting tumor antigens and releasing immune factors, has shown significant advancements in the treatment of hematological malignancies. However, its application in solid tumors, including osteosarcoma, is constrained by factors such as low antigen specificity, limited persistence, and the complex tumor microenvironment. Research on osteosarcoma is ongoing, and some targets have shown promising results in pre-clinical studies. This review summarizes the current status of research on CAR-T cell therapy for osteosarcoma by compiling recent literature. It also proposes future research directions to enhance the treatment of osteosarcoma.

show abstract

Section: Folate Receptor and Ec17mentioning

confidence: 99%

Current status and future challenges of CAR-T cell therapy for osteosarcoma

Li,

Zhang,

Shang

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Consequently, considering the drug's intended destination being a cancer cell, this system is aptly referred to as tumor‐targeting drug delivery. [ 58,59 ]…”

Section: Introductionmentioning

confidence: 99%

“…Consequently, considering the drug's intended destination being a cancer cell, this system is aptly referred to as tumor-targeting drug delivery. [58,59] Moreover, ZnO NPs exhibit distinctive physicochemical attributes, including robust piezoelectric and pyroelectric properties, rendering them responsive to mechanical and thermal variations. [60][61][62][63][64] These attributes could be harnessed in advanced DDSs designed to respond to specific physiological changes.…”

Section: Introductionmentioning

confidence: 99%

A Data Mining Study of Zinc Oxide Nanostructures Utilization in Drug Delivery Nanosystems

Valladão,

da Silva,

Souza

2024

Macromolecular Symposia

View full text Add to dashboard Cite

The present investigation offers a thorough bibliometric exploration spotlighting the pivotal utilization of zinc oxide nanostructures, encompassing both zero‐dimensional (0D) nanoparticles and one‐dimensional (1D) nanostructures, within the realm of nanotechnology‐driven drug delivery systems. This analysis particularly illuminates the distinctive potential of these nanostructures in the cancer therapy context, not merely as carriers and deliverers of pharmaceutical agents, but as entities capable of selectively inducing apoptosis in cancer cells through the orchestrated generation of reactive oxygen species (ROS). Recent research endeavors notably underscore the application prospects of ZnO nanostructures in domains like DNA cleavage, bioimaging, and agricultural defense mechanisms. Moreover, the study elucidates the pronounced enhancement in solubility and biocompatibility that these nanostructures bring about when harmoniously integrated into polymeric nanocomposites. Concomitantly, the involvement of polymers in this symbiotic system is unveiled, wherein they play a multifaceted role in dictating release selectivity, thereby facilitating targeted and efficacious interactions with tissues. Functionally engineered polymeric nanocomposites emerge as promising candidates for targeted delivery modalities in cancer treatment, demonstrating an affinity for specific cell receptors and exhibiting enhanced cellular uptake within the size range of 100–200 nm. The study unearths robust associations among pivotal research terminologies through an exhaustive analysis of Link Strength Between Items (LSBI), culminating in the presentation of a cogent map delineating the evolving trends and forthcoming trajectories in this dynamic domain. In summation, this all‐encompassing bibliometric inquiry serves as a poignant testament to the prodigious potential of zinc oxide nanostructures in the realm of forthcoming nanotechnology‐driven drug delivery paradigms.

show abstract

“…Folic acid (FA) is a small‐molecular‐weight vitamin. FA receptors are membrane glycoproteins that are highly expressed on some tumor cell surface 18 . Therefore, FA can be used to modify the exos carrying the drug, causing engineered exos to have specific targeting properties, exerting a killing effect on tumor cells and reducing normal tissue damage 19,20 .…”

Section: Introductionmentioning

confidence: 99%

“…FA receptors are membrane glycoproteins that are highly expressed on some tumor cell surface. 18 Therefore, FA can be used to modify the exos carrying the drug, causing engineered exos to have specific targeting properties, exerting a killing effect on tumor cells and reducing normal tissue damage. 19,20 FA-functionalized exos co-loaded with resveratrol and celastrol demonstrated powerful anti-inflammatory and immunosuppressive activities against LPSstimulated macrophages in vitro.…”

mentioning

confidence: 99%

Folic acid‐decorated astrocytes‐derived exosomes enhanced the effect of temozolomide against glioma

Liu,

Zhang

2024

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

A direct strategy to achieve specific treatments and reduce side effects is through cell type‐specific drug delivery. Exosomes (Exos) can be modified with folic acid (FA) to prepare drug delivery systems targeting tumor cells that highly express FA receptors. This study aimed to produce an exo drug delivery system with FA decoration and temozolomide (TMZ) loading to improve the sustained TMZ release and targeting. We used DSPE‐PEG2000‐FA to modify exos derived from astrocyte U‐87 to prepare FA‐modified exos (Astro‐exo‐FA). TMZ was encapsulated into Astro‐exo‐FA or Astro‐exo through electroporation to produce TMZ@Astro‐exo and TMZ@Astro‐exo‐FA. In vitro drug release was examined using the dialysis bag method. Through cell experiments in vitro and mouse glioma models in vivo, the effect of TMZ@Astro‐exo‐FA on U‐87 cells was determined. Exo properties were not affected by FA modification and TMZ loading. The drug release rate of TMZ@Astro‐exo‐FA was slower. TMZ@Astro‐exo‐FA uptake by U‐87 cells was higher compared to TMZ@Astro‐exo, indicating that TMZ@Astro‐exo‐FA has a stronger targeting toward U‐87 cells. TMZ@Astro‐exo‐FA remarkably reduced U‐87 cell proliferation, migration, and invasion compared with TMZ@Astro‐exo and free TMZ. Treatment with TMZ@Astro‐exo‐FA reduced the side effects of TMZ (minimal change in body weight), prolonged survival, and inhibited tumor growth in mouse glioma models, and its efficacy was stronger than that of TMZ@Astro‐exo and free TMZ. TMZ@Astro‐exo‐FA could enhance the effect of TMZ against glioma, providing novel ideas for drug targeting delivery and exploring exos as drug carriers against glioma.

show abstract

Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors

Cited by 27 publications

References 111 publications

Current status and future challenges of CAR-T cell therapy for osteosarcoma

Current status and future challenges of CAR-T cell therapy for osteosarcoma

A Data Mining Study of Zinc Oxide Nanostructures Utilization in Drug Delivery Nanosystems

Folic acid‐decorated astrocytes‐derived exosomes enhanced the effect of temozolomide against glioma

Contact Info

Product

Resources

About